Illumina commands >80% share of NGS consumables — a razor/blade monopoly where 4-5x annual pull-through on a $890+ NovaSeq X installed base drives highly predictable recurring revenue. Post-GRAIL divestiture, the company is a clean-sheet genomics pure-play with expanding operating margins (18.6% FY2025 → 23%+ guided 2026) and $931M FCF, trading at ~23.6x 2026E non-GAAP EPS — a reasonable entry for a compounder re-accelerating clinical growth. The SomaLogic acquisition ($350M, Jan 2026) adds a proteomics layer that positions Illumina as the multiomics platform, expanding TAM from ~$15B NGS to ~$25B+ genomics+proteomics.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 25% | $185.00 | Clinical consumables sustain double-digit growth through 2027 as population-scale genomics programs expand |
| Base | 50% | $140.00 | FY2026 revenue meets guidance ($4.5-4.6B), with clinical growth offsetting research softness |
| Bear | 25% | $80.00 | Research end-market deterioration deepens — NIH/government funding cuts reduce academic sequencing budgets by >15% |
Research-update — WGS MRD oncology kit + ASCO/BMS + valuation overshoot above base target
Initial coverage — /complete-research ILMN
None mapped.
Positioning skews toward near-term upside